Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

8.10USD
8:16pm IST
Change (% chg)

$-0.10 (-1.22%)
Prev Close
$8.20
Open
$8.25
Day's High
$8.25
Day's Low
$8.05
Volume
16,977
Avg. Vol
138,179
52-wk High
$10.50
52-wk Low
$5.35

Select another date:

Sat, Jan 6 2018

BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​

* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​ Source text: (http://bit.ly/2EciBBu) Further company coverage:

BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus

* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements

BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study

* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study

BRIEF-Corbus Pharma prices underwritten public offering of common stock

* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock

BRIEF-Corbus Pharmaceuticals Holdings announces proposed public offering of common stock

* Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock

BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study

* Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis

BRIEF-Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15

* Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update

Select another date: